In the wake of the Phase III Actimmune fizzle against idiopathic pulmonary fibrosis (IPF) about two weeks ago, InterMune Inc.'s plan to get rid of half its staff to cut costs surprised almost no one, and investors still have chips on a late-stage compound for the same indication as well as - farther back in the pipeline - a therapy for hepatitis C virus. (BioWorld Today) Read More
